Bioavailability and kinetics of maprotiline.
Six male subjects received simultaneously single 50-mg oral doses of a maprotiline hydrochloride tablet and a trideuterated maprotiline hydrochloride aqueous solution. No side effects or other problems were encountered. The blood levels of unlabeled and isotope-labeled maprotiline for each subject were essentially superimposable. Peak levels, averaging about 50 ng/ml, were attained between 8 and 24 hr after drug. The biologic t1/2 (beta-phase) averaged 58 hr for the unlabeled and 60.5 hr for the labeled drug. The total areas under the curves (extended to time infinity) averaged 3,862 and 3,944 ng . hr/ml for maprotiline and trideuterated maprotiline, respectively (differences between the two are not significant). At the 95% degree of confidence the Westlake confidence limits show less than 10% differences between the formulations with respect to area under the curve data (calculated both to 168 hr and extended to time infinity), peak blood levels, and biologic t1/2s. There were no differences between formulations with respect to times of peak concentrations. Estimates were made for apparent volumes of distribution (about 1,000 l), apparent blood clearance (about 14 l/hr), lag times (about 1.42 hr for tablets and 1.31 hr for solution), and absorption rate constants (about 0.34 hr-1 for the tablets and 0.42 hr-1 for the solution).
D000328:Adult; D000873:Anthracenes / Q000378:metabolism*; D001682:Biological Availability; D006801:Humans; D007408:Intestinal Absorption; D007700:Kinetics; D008297:Male; D008376:Maprotiline / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D008875:Middle Aged; D012996:Solutions; D013607:Tablets
D000873:Anthracenes; D012996:Solutions; D013607:Tablets; D008376:Maprotiline